TRANSGENE BIOTEK LTD.
Latest filings
- Newspaper publication of Q1 FY27 unaudited financial results · Compliance
- Q1 FY27 results: revenue up 21%, but loss narrows to Rs 38.9 lakh · Results
- Transgene Biotek Q1 FY27 results: loss narrows to Rs 38.9 lakh, revenue up 21% · Results
- Board meeting on Aug 7 to consider Q1 FY27 results and AGM extension · Results
- Regulation 57 compliance: no NCDs with payments due in Q1 FY27 · Compliance
- Transgene Biotek says Reg 32 deviation report not applicable for Q1 FY27 · Compliance
- Reg 57(5) of SEBI LODR not applicable for Q1 FY27 · Compliance
- Filing of Reg 74(5) compliance certificate for Q1 FY27 · Compliance
- Trading Window Closure Ahead of Q1 FY27 Results · Compliance
- Newspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. · Compliance
- Audited Financial Results · Results
- This has reference to our letter dated May 13, 2026, The Board of Directors of the Company at their meeting held on May 29, 2026 have resolved as follows: Pursuant to Regulation 33 of .... · Results
- Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve To Consider and approve the .... · Results
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
- Non-Applicability of Regulation 32(1) of SEBI. · Compliance
- Compliance filing under SEBI Reg 57(4) for Q4 FY2026 · Compliance
- Non-Applicability of Reg -57 (5) of SEBI LODR Regulations, 2015. · Compliance
- Compliance certificate 7(3) · Compliance
- Compliances Certificate under 74 (5) of SEBI · Compliance
- Closure of Trading Window · Compliance
- Newspaper Publication · Compliance
- Financial Results of the Company, for the quarter 31-12-2025. · Results
- Dear Sir/Madam, This has reference to our letter dated January 28 2026. 1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the .... · Results
- General Announcements · Regulatory & Legal
- Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 1) To consider and approve .... · Results
- Statement of Deviation & Variation · Compliance
- Compliance -57 (5) · Compliance
- Compliance -57 (4) · Compliance
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
- Compliances -Certificate under Reg.74(5) of SEBI. · Compliance
- OUT COME RESULTS AND SCRUTINIZER REPORTS · Board & Shareholder Meetings
- OUT COME OF VOTING AT 35TH AGM · Board & Shareholder Meetings
- Outcome of 35th AGM · Board & Shareholder Meetings
- Newspaper Advertisement - Notice of 35th Annual General Meeting, Remote E-Voting information, Record date and Book Closure etc. · Compliance
- Intimation of Closure of Trading Window. · Compliance
- Intimation of Book Closure and cut -off date · Board & Shareholder Meetings
- 35th Annual Report for the year ended 31st March, 2025 . · Results
- Newspaper Advertisement of financial results under regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. · Compliance
- Un-Audited Financial Results · Results
- We wish to inform you that the Board of Directors of the Company at its meeting held on Friday, November 14, 2025, has considered and approved the following matters: · Results
- Transgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve to consider and approve the .... · Results
- Declaration under clause 36 · Regulatory & Legal
- Compliance 57(4) as on 30th September 2025 · Compliance
- Compliance under 57(5) as on 30th September 2025 · Compliance
- Compliances Certificate · Compliance
- Compliance Certificate · Compliance
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
- Statement of Deviation & Variation · Compliance
- Closure of Trading Window · Compliance
- The AGM of the Company for the financial year 31-03-2025 will be held on or before December 31, 2025, instead of the earlier due date of 30-09-2025. A copy of the approval letter received .... · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
A Healthcare Services company listed on BSE, reporting revenue of ₹0 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from TRANSGENE BIOTEK LTD.'s filed financials and exchange disclosures
What does TRANSGENE BIOTEK LTD. do?
TRANSGENE BIOTEK LTD. is a Healthcare Services company listed on BSE.
Is TRANSGENE BIOTEK LTD. profitable?
No. Over the trailing twelve months TRANSGENE BIOTEK LTD. reported a net loss of ₹2 Cr on revenue of ₹0 Cr.
Does TRANSGENE BIOTEK LTD. pay a dividend?
Not in the latest reported year — TRANSGENE BIOTEK LTD.'s dividend payout for FY26 was nil.
Is TRANSGENE BIOTEK LTD. debt-free?
No. Debt stands at 2.05× equity, and it carries net debt of ₹17 Cr. That is lower than 0% of its 26 Healthcare Service Provider peers.
Is TRANSGENE BIOTEK LTD. expensive compared with its peers?
On trailing P/E, TRANSGENE BIOTEK LTD. ranks 8 of 29 in Healthcare Service Provider — cheaper than 75% of them, against an industry median of 22.9×. This is a position, not a valuation judgement.
How much does the TRANSGENE BIOTEK LTD. share price move in a day?
On a typical session TRANSGENE BIOTEK LTD. moves 2.56% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track TRANSGENE BIOTEK LTD.'s announcements?
Every NSE and BSE filing by TRANSGENE BIOTEK LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.